iRegene Therapeutics Co., Ltd.
iRegene Therapeutics Co., Ltd.
Explore linked clinical trials.8 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| The Safety and Efficacy of NouvSoma001 in Neuromyelitis Optica Spectrum Disorders | CNS demyelinating autoimmune disease, acute transverse myelitis, autoimmune disease, autoimmune disorder of the nervous system, cranial nerve neuropathy, demyelinating disease, eye disorder, immune system disorder, nervous system disorder, neuromyelitis optica, optic nerve disorder, optic neuritis | Recruiting | Phase 1 | 2026-09-21 | NCT06620809 | |
| This Clinical Trial is Designed to Evaluate the Safety, Tolerability, Feasibility and Preliminary Efficacy of NouvNeu001 (Human Dopaminergic Progenitor Cells Injection) in Patients With Parkinson's Disease. | Parkinson disease, basal ganglia disorder, brain disorder, central nervous system disorder, movement disorder, nervous system disorder, neurodegenerative disease, parkinsonian disorder, synucleinopathy | Recruiting | Phase 1 / Phase 2 | 2026-05-11 | NCT07102342 | |
| Phase I Clinical Study of NouvNeu001 Injection for the Treatment of Moderate-to-Advanced Parkinson's Disease in Patients Who Have Previously Undergone Deep Brain Stimulation or Deep Brain Nucleus Lesioning Surgery | Parkinson disease, basal ganglia disorder, brain disorder, central nervous system disorder, movement disorder, nervous system disorder, neurodegenerative disease, parkinsonian disorder, synucleinopathy | Not yet recruiting | Phase 1 | 2026-04-24 | NCT07550374 | |
| A Phase I/III Clinical Study to Evaluate NouvNeu001 Injection for Multiple System Atrophy | Multiple System Atrophy - Parkinsonian Subtype (MSA-P) | Recruiting | Phase 1 | 2026-04-14 | NCT07289477 | |
| The Safety and Efficacy of NouvSoma001 in Ischemic Stroke | brain disorder, cardiovascular disorder, central nervous system disorder, cerebrovascular disorder, ischemic stroke, nervous system disorder, stroke disorder, vascular disorder | Recruiting | Phase 1 | 2026-01-21 | NCT06612710 | |
| The Safety, Feasibility and Efficacy of NouvNeu001 for Parkinson's Disease | Parkinson disease, basal ganglia disorder, brain disorder, central nervous system disorder, movement disorder, nervous system disorder, neurodegenerative disease, parkinsonian disorder, synucleinopathy | Not yet recruiting | Phase 2 | 2025-06-29 | NCT07028632 | |
| The Safety, Tolerability and Preliminary Efficacy of NouvNeu001 for Early-onset Parkinson's Disease | basal ganglia disorder, brain disorder, central nervous system disorder, movement disorder, nervous system disorder, parkinsonian disorder | Recruiting | Phase 1 | 2024-11-07 | NCT06608355 | |
| The Safety, Tolerability and Efficacy of NouvNeu001 for Parkinson's Disease | Parkinson disease, basal ganglia disorder, brain disorder, central nervous system disorder, movement disorder, nervous system disorder, neurodegenerative disease, parkinsonian disorder, synucleinopathy | Recruiting | Phase 1 / Phase 2 | 2024-11-01 | NCT06167681 |